ReviewStem cell research & therapy2026
Bone marrow-derived mesenchymal stem cells for ischemic stroke: mechanisms, delivery strategies, clinical evidence, and translational challenges.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ischemic stroke remains a major global health burden because of its high incidence, disability, and mortality. Current reperfusion therapies are constrained by narrow therapeutic windows and have limited capacity to reverse established neuronal injury or promote long-term functional recovery, highlighting the need for strategies that support neural repair and neurovascular remodeling. Bone marrow-derived mesenchymal stem cells (BMSCs) have been widely investigated as candidate therapeutic products for ischemic stroke because of their paracrine, immunomodulatory, trophic, angiogenic, and microenvironment-regulating properties. Current evidence suggests that their therapeutic effects are more likely mediated by regulation of the post-ischemic microenvironment than by direct neuronal replacement. This narrative review discusses BMSC-based strategies for ischemic stroke by integrating evidence from preclinical models, early clinical studies, and translational research. We summarize major proposed mechanisms, including regulation of neuroinflammation, suppression of apoptosis and oxidative stress, blood-brain barrier protection, angiogenesis, neurotrophic support, axonal remodeling, and myelin repair. Emerging mechanisms, such as autophagy regulation, mitochondrial transfer, and extracellular vesicle-mediated effects, are also discussed according to their current level of evidence. In addition, this review evaluates delivery routes, functional enhancement strategies, BMSC-derived extracellular vesicles, combination approaches, clinical evidence, and key translational barriers. Particular attention is given to the distinction between experimentally supported mechanisms, early clinical safety and feasibility signals, and unresolved issues related to optimal dose, administration timing, route-dependent biodistribution, product heterogeneity, mechanism-linked potency assays, and Good Manufacturing Practice-compatible manufacturing. This review provides a balanced framework for understanding the therapeutic potential, current limitations, and future development requirements of BMSC-based therapies for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.